D-0639-2020 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0639-2020 was initiated by Glenmark Pharmaceuticals Inc., USA on Dec 17, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is ongoing. Affected quantity: 208,668 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2020
Initiation Date
Dec 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
208,668 bottles

Product description

Glenmark Ranitidine Tablets USP 150 mg Rx Only 60 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-248-60

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Natiowide

Code information

7701164A 7701471A 7701670B 7701827A 7702242A 7702705A 7702947A 7703408A 7704494A 7704495A 19190289 19190342 19190372 7702737A

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0639-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0639-2020. Report a data issue: hello@regdatalab.com.